Shows reduced toxicity with cetuximab versus cisplatin in KRAS-variant patients, suggesting biomarkers merit further study.
Possible lower LRF and less acute toxicity with cetuximab versus cisplatin for KRAS-variant patients appear to be offset by potentially increased late toxicity. Further evaluation of this class of biomarkers is warranted.
No takes yet. Share an insight, caveat, or question.
Paik et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: